Paul Hudson, Sanofi CEO (Raphael Lafargue/Abaca/Sipa USA; Sipa via AP Images)

Sanofi picks up Kad­mon and its trans­plant drug in $1.9B buy­out, giv­ing Sam Wak­sal 2 Big Phar­ma buy­outs un­der his belt

It’s not just hot spaces that Paul Hud­son wants Sanofi to lead in.

The CEO’s lat­est, $1.9 bil­lion M&A gam­ble points straight to Kad­mon $KDMN and its new­ly ap­proved drug, Rezurock, which is billed as a first-in-class treat­ment for chron­ic graft-ver­sus-host dis­ease — and a strong ad­di­tion to Sanofi’s trans­plant port­fo­lio.

For Kad­mon, the buy­out marks a sweet re­ward at the end of an up­hill jour­ney that spanned more than a decade and vin­di­ca­tion for a no­to­ri­ous name in biotech, even if the ul­ti­mate price is ac­tu­al­ly low­er than its IPO price five years ago.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.